Awakn Life Sciences Announces Its Second Location in the UK for "Awakn Clinics London," Providing Treatment to the Largest City in the UK

The clinic will deliver psychedelic-assisted psychotherapy treatments for Addiction and other mental health conditions and is scheduled to open during the fourth quarter of 2021.

Awakn Clinics London will join Awakn Clinics Bristol as the only clinics in the world providing evidence backed Ketamine-Assisted Psychotherapy for Alcohol Use Disorder.

Awakn Life Sciences Corp. (NEO: AWKN) (OTC Pink: AWKNF) ('Awakn'), a biotechnology company with clinical operations developing and delivering psychedelic medicines to better treat Addiction, today announced the signing of its 10-year lease to open Awakn Clinics London, a psychedelic-focused therapy center to treat Addiction and other mental health conditions.

Awakn Clinics London, a 5,000 square-foot, 8 treatment room clinic, will deliver psychedelic-assisted psychotherapy treatments, such as ketamine-assisted therapies. The clinic launch is a response to the growing global population suffering from Addiction, including alcohol and other mental health conditions. According to the report "Global Burden of Disease," mental health illnesses and addictions are thefifth leading cause of illness, affecting 20% of the global population.

Awakn Clinics London will be owned and operated by Awakn and will be led by on-site psychiatrists. Awakn Clinics London will deliver ketamine-assisted psychotherapy in the near term and will utilize MDMA therapies as and when marketing and regulatory authorization is granted.

Anthony Tennyson, Awakn's CEO commented, "A significant majority of people globally have been either directly or indirectly affected by Addiction or mental health conditions. Suffering themselves or having family or friends whose lives have been upended by these conditions. The opening of Awakn Clinics London marks a significant milestone not only for Awakn, but for the people of London who have been suffering with Addiction and mental health conditions."

Awakn has partnered with Onefine_Day, specialists in designing places that deliver meaningful outcomes and better connections for a brand's audience, creating places, not spaces. Awakn Clinics London will be designed to offer a warm and welcoming experience to demonstrate first-hand how psychedelics can transform the lives of patients. Following a client-centered design approach, the clinic space will showcase an evidence-based environmental design focused on patient wellbeing and supports the right context for effective treatment. The clinic is expected to finish the completion of renovations and design by October with the grand opening during the fourth quarter of 2021. The clinic is located on Duke's Road, near the UCL Hospital and the British Medical Association.

Awakn Clinics London will be the second of three Awakn clinics to open this year in the UK. Awakn Clinics Bristol is due to open in late Q3, with the Manchester clinic to follow on from London's opening in late Q4.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92041